Latest in: tech transfer
Featured Image

Cracking the Code Of Biotech Valuation – ambiom on BeyondBiotech podcast

We spoke in detail about our activities at BeyondBiotech podcast, you can listen to the episode here: https://podcast.labiotech.eu/1995493/episodes/16219760-cracking-the-code-of-biotech-valuations
gravatar
 · 
December 10, 2024
Featured Image

ambiom has presented the practical experience in technology transfer at the BioCentre in Zagreb, Croatia

On the 20th of February 2024, we have had the opportunity to present our experience and know-how on the online webinar hosted by the BioCentre in Zagreb, to the audience of early-stage life science …
gravatar
 · 
March 2, 2024
Featured Image

Pharma Valuation 101: NPV vs rNPV in Drug Development

Drug development is a complex and resource-intensive process that involves significant investments in research, clinical trials, and regulatory activities. As pharmaceutical companies evaluate the potential of assets they employ various financial metrics. Two commonly …
gravatar
 · 
October 6, 2023
Featured Image

A Freedom-To-Operate analysis – do you need to bother?

When a company is in the process of strategizing the development and release of a new product, a notable concern arises, especially in technology-driven fields abundant with patents. The risk is the potential impedance …
gravatar
 · 
August 11, 2023

Impressum

ambiom s.r.o.
Karpatské námestie 7770/10A
831 06 Bratislava
IČO: 54219035

Contact

info@ambiom.com
+421 948 652 276

footer-FB
footer-Li
Footer-Insta

Newsletter

Back to top Arrow